Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Korsana Biosciences's total debt was $3.50M at Dec 31, 2022. For fiscal 2022 it was $3.50M, up 0.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.50M | 0.0% |
| FY2021 | Dec 31, 2021 | $3.50M | 0.0% |
| FY2020 | Dec 31, 2020 | $3.50M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | $3.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $3.50M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.50M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.50M | – |
See a number that looks wrong?